http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2742442-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73e0d5808f34f512649e277bd216a344 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 |
| filingDate | 2013-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2a13630b16c1233dc6b41416a6fa0cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_617374da7196c56e70e93febc7fe7e69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df4b369395ae7cfa29a8e81d2d45f3f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b9fd6f58d38097f980ffbb44d977fda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca3ba3dd9287d8514f9f0b5e96f3e258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dedf094d8ac263d1f435e625bc4d469d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7dc8c847599bd0cd0485d8a541e063c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0b884943016c7754cd10c178fe4d1ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e095c14fdf1de2b02052be8620f2edab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_333a12ff02ddc2c512f45296a5f785b6 |
| publicationDate | 2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2742442-T3 |
| titleOfInvention | Inhibitor compounds |
| abstract | A compound of formula I shown below, or a pharmaceutically acceptable salt or solvate thereof: ** Formula ** wherein: W is N or C-R3; X is CH or N; Z is N or C-H; R1 is selected from chloro, (1-6C) alkyl, (1-8C) heteroalkyl, aryl, aryl (1-2C) alkyl, heteroaryl, heteroaryl (1-2C) alkyl, heterocyclyl, heterocyclyl (1-2C) alkyl, (3-8C) cycloalkyl, (3-8C) cycloalkyl (1-2C) alkyl, NR7R8, OR9, C (O) R9, C (O) OR9, OC (O) R9, N (R10) OR9, N ( R10) C (O) OR9, C (O) N (R10) R9, N (R10) C (O) R9, S (O) pR9 (where p is 0 or 1), SO2N (R10) R9, N ( R10) SO2R9, N (R10) SOR9 or SON (R10) R9; and wherein R1 is optionally substituted with one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, (1-4C) alkyl, (1-4C) alkoxy , S (O) qCH3 (where q is 0, 1 or 2), methylamino or dimethylamino, aryl, aryl (1-2C) alkyl, heteroaryl, heteroaryl (1-2C) alkyl, heterocyclyl, heterocyclyl (1-2C) alkyl , (3-8C) cycloalkyl, or (3-8C) cycloalkyl (1-2C) alkyl, and wherein any (1-4C) alkyl, (1-4C) alkoxy, aryl, heteroaryl, heterocyclyl, or ( 3-8C) Cycloalkyl present within a substituent group on R1 is optionally further substituted by fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, (1-4C) alkyl, NRaRb, ORa , C (O) Ra, C (O) ORa, OC (O) Ra, N (Rb) ORa, C (O) N (Rb) Ra, N (Rb) C (O) Ra, S (O) pRa (where p is 0, 1 or 2), SO2N (Rb) Ra, or N (Rb) SO2Ra, where Ra and Rb are each independently selected d and H or (1-4C) alkyl; R3 is hydrogen, (1-4C) alkyl, (3-6C) cycloalkyl, halo, CF3, CN and (1-4C) alkoxy; R4 is hydrogen, (1-3C) alkyl, (1-3C) alkoxy, fluoro, chloro or CF3; Ar has the formula: ** Formula ** where: (i) all of A1, A2 and A3 are CH; (ii) one of A1, A2 and A3 is N and the others are CH; or (iii) two of A1, A2 and A3 are N and the other is CH; R5 is selected from hydrogen, cyano, (1-3C) alkyl, (1-3C) fluoroalkyl, (1-3C) alkoxy, (1-3C) fluoroalkoxy, halo, (1-3C) alkanoyl, C (O) NR15R16 or S (O) 2NR15R16, and wherein R15 and R16 are each independently selected from H or (1-3C) alkyl, and wherein any alkyl or alkoxy framework units present within a substituent group R5 are optionally further substituted by hydroxy or methoxy; R6 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, ureido, (1-6C) alkyl, (2-6C) alkenyl, (2-6C) alkynyl, or R6 is a group of the formula: -L1-L2-R17 where L1 is absent or is a linking group of the formula - [CR18R19] n- where n is an integer selected from 1, 2, 3 or 4, and R18 and R19 are each independently selected from hydrogen or (1-2C) alkyl; L2 is absent or selected from O, S, SO, SO2, N (R20), C (O), C (O) O, OC (O), CH (OR20), C (O) N (R20), N (R20) C (O), N (R20) C (O) N (R21), S (O) 2N (R20), or N (R21) SO2, where R20 and R21 are each independently selected from hydrogen or (1-2C) alkyl; and R17 is (1-6C) alkyl, aryl, aryl- (1-6C) alkyl, (3-6C) cycloalkyl, (3-6C) cycloalkyl- (1-4C) alkyl, heteroaryl, heteroaryl- (1-4C) ) alkyl, heterocyclyl, heterocyclyl- (1-4C) alkyl, and wherein R17 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, NR22R23, (1-4C) alkoxy, (1-4C) alkyl, (3-8C) cycloalkyl, (3-8C) cycloalkyl- (1-3C) alkyl, (1-5C) alkanoyl, (1-5C) alkylsulfonyl, heterocyclyl, heterocyclyl- (1-2C ) alkyl, heteroaryl, heteroaryl- (1-2C) alkyl, CONR22R23, and SO2NR22R23; wherein R22 and R23 are each independently selected from hydrogen, (1-4C) alkyl or (3-6C) cycloalkyl or (3-6C) cycloalkyl (1-2C) alkyl; and wherein when said substituent group comprises an alkyl, cycloalkyl, heterocyclyl or heteroaryl structural unit then said structural unit is optionally further substituted by hydroxy, fluoro, chloro, cyano, CF3, OCF3, (1-2C) alkyl, (1-2C) ) alkoxy, SO2 (1-2C) alkyl or NReRf (where Re and Rf are each independently selected from hydrogen, (1-3C) alkyl, (3-6C) cycloalkyl, or (3-6C) cycloalkyl (1-2C ) alkyl); or R17 is a group having the formula: -L3-L4-R24 L3 is absent or is a linking group of the formula - [CR25R26] n- where n is an integer selected from 1, 2, 3 or 4, and R25 and R26 are each independently selected from hydrogen or (1-2C) alkyl; L4 is absent or selected from O, S, SO, SO2, N (R27), C (O), C (O) O, OC (O), CH (OR27), C (O) N (R27), N (R27) C (O), N (R27) C (O) N (R28), S (O) 2N (R27), or N (R28) SO2, where R27 and R28 are each independently selected from hydrogen or (1-2C) alkyl; and R24 is (1-6C) alkyl, aryl, aryl- (1-6C) alkyl, (3-6C) cycloalkyl, (3-6C) cycloalkyl- (1-4C) alkyl, heteroaryl, heteroaryl- (1-4C) ) alkyl, heterocyclyl, heterocyclyl- (1-4C) alkyl; R8 and R9 are each independently selected from hydrogen, (1-6C) alkyl, (1-6C) alkoxy, (3-9C) cycloalkyl, (3-9C) cycloalkyl- (1-2C) alkyl, aryl, aryl- (1-2C) alkyl, heterocyclyl, heterocyclyl- (1-2C) alkyl, heteroaryl, heteroaryl- (1- 2C) alkyl, and wherein R8 and R9 are optionally further substituted by one or more substituents selected from hydroxy, fluoro, chlorine, cyano, CF3, OCF3 (1-2C) alkyl or (1-2C) alkoxy; R7 and R10 are independently selected from hydrogen, (1-6C) alkyl, (3-6C) cycloalkyl, (3-6C) cycloalkyl- (1-2C) alkyl, and wherein R7 and R10 are optionally further substituted by one or plus selected substituents of hydroxy, fluoro, chloro, cyano, CF3, OCF3, (1-2C) alkyl or (1-2C) alkoxy; wherein the terms "heterocyclyl" and "heterocyclic" mean a monocyclic, fused, bridged, or spirobicyclic saturated or partially saturated non-aromatic heterocyclic ring system; and wherein the term "heteroaryl" means a mono-, bi-, or polycyclic aromatic ring incorporating one or more heteroatoms selected from nitrogen, oxygen, or sulfur, and partially aromatic bicyclic or polycyclic ring systems where at least one ring is a aromatic ring and one or more of the other rings is a non-aromatic ring, saturated or partially saturated, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur subject to the condition that: X is only N when Z is N; and for use in the treatment of cancer, wherein the cancer is selected from cancer of the lung, colon, breast, ovary, prostate, liver, pancreas, brain, and skin. |
| priorityDate | 2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 602.